SecBot SecBot
SECBOTREPLAY Home › Report › ABBV

ABBV · AbbVie entered into an underwriting agreement to issue and sell $10.0…

AbbVie Inc. · 8-K filed Aug 5, 2026 at 17:17 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Aug 5, 2026 at 17:17 ET

AbbVie entered into an underwriting agreement to issue and sell $10.0 billion aggregate principal amount of senior notes across nine tranches, with net proceeds of approximately $9.93 billion. The funds will partially finance the acquisition of Apogee Therapeutics and reduce commitments under a $10.0 billion delayed draw term loan facility. This is a routine debt capital markets transaction for a large investment-grade issuer, increasing leverage but securing financing for a strategic acquisition.

  • AbbVie issued $10.0 billion aggregate principal amount of senior notes across nine tranches with maturities from 2028 to 2066.
  • Net proceeds are expected to be approximately $9.93 billion.
  • Proceeds will fund a portion of the cash payment obligations for the acquisition of Apogee Therapeutics, Inc. and for general corporate purposes.
  • The issuance will reduce commitments under AbbVie's $10.0 billion 364-day delayed draw term loan facility entered into in connection with the Apogee acquisition.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access